RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities Business Wire NOKOMIS, Fla. -- April 24, 2013 In a bid to expand the market for its biotech innovations beyond North America, Rainbow Coral Corp. (OTCBB: RBCC) is seeking out new overseas targets that stand to benefit from adding licenses for the drug delivery protocols that its joint venture partner, TheraKine, has developed. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015. TheraKine is a leader in this marketplace, having developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery that allow for lower drug concentrations and significantly reduced risk of drug toxicity. In order to build market share in this fast-growing sector, RBCC is looking for overseas healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. “Licensing is the key to making this a successful partnership with TheraKine,” said RBCC CEO Patrick Brown. “Together, we can spread this revolutionary technology around the globe to the doctors and patients who need it most.” For more information on Rainbow BioSciences’ personalized medicine initiatives, please visitwww.rainbowbiosciences.com/investors.html. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN). About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. Contact: Rainbow Coral Corp. Patrick Brown, 850-269-7230 President and CEO firstname.lastname@example.org
RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities
Press spacebar to pause and continue. Press esc to stop.